Pharmacotherapy of erectile dysfunction – where we are today and where we are going

Česká verzia

Authors: J. Bultas ¹; D. Karetová ²
Authors place of work: Farmakologický ústav, 3. LF UK, Praha ¹; II. interní klinika – klinika kardiologie a angiologie 1. LF UK a VFN v Praze ²
Published in the journal: Kardiol Rev Int Med 2014, 16(4): 281-287
Category: Cardiology Review

Summary

This review article summarizes current findings regarding the mechanism of induction of erection and contemporary possibilities of pharmacotherapy for erectile dysfunction. The next part summarizes the characteristics of phosphodiesterase enzymes and the significance of their inhibition in general, with special emphasis on phosphodiesterase type 5 (PDE-5) isoenzyme. After this, the characteristics of the individual representatives of PDE-5 inhibitors – sildenafil, vardenafil, tadalafil and avanafil – are discussed from the point of view of effectiveness, safety and drug interactions. The last part of the article sums up the authors´ knowledge and experiences concerning the influence of several cardiovascular drugs on erectile function and dysfunction.

Keywords:
pharmacotherapy – erectile dysfunction – phosphodiesterase type 5 inhibitors – sildenafil – vardenafil – tadalafil – avanafil

Zdroje

1. Vlachopoulos C, Terentes‑ Printzios D, Ioakeimidis N et al. Prediction of cardiovascular events and all‑cause mortality with erectile dysfunction: a systematic review and meta‑analysis of cohort studies. Circ Cardiovasc Qual Outcomes 2013; 6: 99– 109. doi: 10.1161/ CIRCOUTCOMES.112.966903.

2. Karakeci A, Firdolas F, Ozan T et al. Second pathways in the pathophysiology of ischemic priapism and treatment alternatives. Urology 2013; 82: 625– 629. doi: 10.1016/ j.urology.2013.06.029.

3. Fraga‑ Silva RA, Montecucco F, Mach F et al. Pathophysiological role of the renin‑angiotensin system on erectile dysfunction. Eur J Clin Invest 2013; 43:978– 985. doi: 10.1111/ eci.12117.

4. Klotz T, Mathers MJ, Braun M et al. Effectiveness of oral L‑ arginine in first‑line treatment of erectile dysfunction in a controlled crossover study. Urol Int 1999; 63: 220– 223.

5. Baraldi PG, Tabrizi MA, Fruttarolo F et al. Recent improvements in the development of A(2B) adenosine receptor agonists. Purinergic Signalling 2008; 4: 287– 303. doi: 10.1007/ s11302‑ 008‑ 9097‑ z.

6. Lasker GF, Pankey EA, Kadowitz PJ. Modulation of soluble guanylate cyclase for the treatment of erectile dysfunction. Physiology (Bethesda) 2013; 28: 262– 269. doi: 10.1152/ physiol.00001.2013.

7. da Costa Gonçalves AC, Fraga‑ Silva RA, Leite R et al. AVE 0991, a non‑peptide Mas‑ receptor agonist, facilitates penile erection. Exp Physiol 2013; 98: 850– 855. doi: 10.1113/ expphysiol.2012.068551.

8. Zhang XH, Aydin M, Kuppam D et al. In vitro and in vivo relaxation of corpus cavernosum smooth muscle by the selective myosin II inhibitor, blebbistatin. J Sex Med 2009; 6: 2661– 2671. doi: 10.1111/ j.1743‑ 6109.2009.01424.x.

9. Tsertsvadze A, Fink HA, Yazdi F et al. Oral phosphodiesterase‑ 5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta‑analysis. Ann Intern Med 2009; 151: 650– 661. doi: 10.7326/ 0003‑ 4819‑ 151‑ 9‑ 200911030‑ 00150.

10. Asimakopoulos AD, Miano R, Finazzi Agrò E et al. Does current scientific and clinical evidence support the use of phosphodiesterase type 5 inhibitors for the treatment of premature ejaculation? A systematic review and meta‑analysis. J Sex Med 2012; 9: 2404– 2416. doi: 10.1111/ j.1743‑ 6109.2011.02628.x.

11. Yuan J, Zhang R, Yang Z et al. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta‑analysis. Eur Urol 2013; 63: 902– 912. doi: 10.1016/ j.eururo.2013.01.012.

12. Giuliano F, Jackson G, Montorsi F et al. Safety of sildenafil citrate: review of 67 double‑blind placebo‑ controlled trials and the postmarketing safety database. Int J Clin Pract 2010; 64: 240– 255. doi: 10.1111/ j.1742‑ 1241.2009.02254.x.

13. Wang R, Burnett AL, Heller WH et al. Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability. J Sex Med 2012; 9: 2122– 2129. doi: 10.1111/ j.1743‑ 6109.2012.02822.x.

14. Webb DJ, Muirhead GJ, Wulff M et al. Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. J Am Coll Cardiol 2000; 36: 25– 31.

15. Baumhäkel M, Schlimmer N, Kratz M et al. Cardiovascular risk, drugs and erectile function – a systematic analysis. Int J Clin Pract 2011; 65: 289– 298. doi: 10.1111/ j.1742‑ 1241.2010.02563.x.

16. Silvestri A, Galetta P, Cerquetani E et al. Report of erectile dysfunction after therapy with beta‑blockers is related to patient knowledge of side effects and is reversed by placebo. Eur Heart J 2003; 24: 1928– 1932.

17. Yang L, Yu J, Ma R et al. The effect of combined antihypertensive treatment (felodipine with either irbesartan or metoprolol. on erectile function: a randomized controlled trial. Cardiology 2013; 125: 235– 241. doi: 10.1159/ 000350955.

18. Fraga‑ Silva RA, Montecucco F, Mach F et al. Pathophysiological role of the renin‑angiotensin system on erectile dysfunction. Eur J Clin Invest 2013; 43: 978– 985. doi: 10.1111/ eci.12117.

19. Miner M, Billups KL. Erectile dysfunction and dyslipidemia: relevance and role of phosphodiesterase type‑ 5 inhibitors and statins. J Sex Med 2008; 5: 1066– 1067. doi: 10.1111/ j.1743‑ 6109.2008.00783.x.